LONDON (Alliance News) - BTG PLC, the specialist healthcare company, Thursday announced that Health Canada has approved Varithena, its polidocanol injectable foam for the treatment of varicose veins.
BTG said that an estimated 3.7 million Canadians have varicose veins, with women twice as likely as men to develop varicosities.
The company also said that there are certain warnings and precautions that need to be understood before using Verithena. Varithena is contraindicated in patients with known allergy to polidocanol and those with acute thromboembolic disease.
"We are pleased to receive approval in Canada for Varithena and look forward to the commercial launch during the first half of 2016. The controlled launch continues in the US reimbursed sector, where we consistently receive excellent feedback from physicians in relation to clinical performance and patient acceptability. We are also progressing development of related products for other venous disorders," said Chief Executive Officer Louise Makin.
By Preten Patel; pretenpatel@alliancenews.com
Copyright 2015 Alliance News Limited. All Rights Reserved.
